Browsing Category
Pharma Industry News
4730 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Will Novartis’ oral drug iptacopan change the game in myasthenia gravis treatment?
Novartis gains FDA orphan designation for iptacopan in myasthenia gravis. Explore how this oral drug could shift neurology and rare disease strategy.
FDA approves Cytokinetics’ MYQORZO for obstructive HCM after SEQUOIA-HCM trial success
FDA approves Cytokinetics’ aficamten for obstructive HCM. Find out what this means for cardiologists, patients, and rival Camzyos as MYQORZO prepares to launch.
Amgen (NASDAQ: AMGN) expands TrumpRx pricing deal, offers Aimovig and Amjevita at $299
Amgen cuts U.S. drug prices for Aimovig and Amjevita under TrumpRx, citing earlier investments in Ohio and North Carolina. See what this signals for big pharma.
Why Bristol Myers Squibb is giving away Eliquis to Medicaid and what it signals for U.S. drug pricing next
Bristol Myers Squibb will offer Eliquis free to Medicaid under a U.S. pricing deal. Find out what it means for drug pricing, investors, and patients.
Hansa Biopharma targets Q3 2026 approval for imlifidase with Priority Review request
Hansa Biopharma submits imlifidase BLA to the FDA, aiming to transform access to kidney transplants for highly sensitized patients. Read more on what’s next.
Meiji Seika Pharma partners with MBC BioLabs to tap early-stage biotech innovation in the U.S.
Meiji Seika Pharma partners with MBC BioLabs to tap early-stage U.S. biotech startups. Find out what this means for its global drug discovery strategy.
Zasocitinib meets all endpoints in Phase 3 trials, Takeda (NYSE: TAK) eyes FDA submission in 2026
Takeda’s once-daily TYK2 pill hits PASI 100 in Phase 3 psoriasis trials. Find out what this means for rivals, regulators, and Takeda’s pipeline strategy.
PADCEV plus Keytruda shows survival benefit in muscle-invasive bladder cancer regardless of cisplatin eligibility
PADCEV plus Keytruda shows significant survival benefit in cisplatin-eligible muscle-invasive bladder cancer. Find out what the EV-304 data means for treatment standards.
Innovent Biologics strengthens mazdutide’s global credibility as Phase 3 diabetes trials land in Nature
Innovent Biologics, Inc. lands back-to-back Nature Phase 3 wins for mazdutide in type 2 diabetes. See what it means for HKEX: 01801.
SGX945 demonstrates lasting oral ulcer reduction in Phase 2 Behçet’s disease trial
Find out how SGX945 achieved durable oral ulcer reduction in a phase 2 Behçet’s disease trial published in Rheumatology (Oxford).